Everyone Deserves Access to Innovation
Our Mission
At ICE Biopharma, our mission guides us. Medical innovation delivered by the healthcare industry means our lives are longer and our quality of life better.
Yet access to innovation is constrained, especially for people suffering from diseases with a high unmet need. The reasons for this lack of access are multifactorial: economic, regulatory and political.
At ICE Biopharma we aim to be part of the solution. By creating a new ecosystem of partnering and collaboration, we want to augment the number of new medicines reaching the hands of patients who will benefit from them.
Because 'Everyone deserves access to innovation'.
Our Partnering Approach
Commercial Partner of Choice
Biotechs want to launch their products in Europe & Canada. However, this step is very costly and requires regional expertise to succeed. ICE Biopharma is committed to become the partner of choice for Biotechs wishing to launch specialty, hospital and orphan/rare products in Europe & Canada, executing on our and our partners' missions to deliver innovation to patients.
A tailored model
We will co-create European & Canadian regulatory strategy. We will negotiate favorable access and reimbursement terms. We will deploy rightsized customer-facing teams for each asset in the major European markets & in Canada, leveraging centralized support functions across our in-licensed product portfolio. We are an International Commercial Engine.
Compelling Deal Terms
We propose license terms that protect the Biotech's P&L, preserve management bandwidth and deliver favourable product NPVs when compared with go-it-alone. Product recovery rights mean a deal with ICE will never become a poison pill for our Biotech Partners.
ICE Biopharma Founders
Francis Marsland, CLO
Sebastian Stachowiak, CEO
Sebastian Stachowiak, CEO
- Over 25 years experience working in pharma and biotech
- Last role: VP, Head of Legal & Compliance, Europe & Middle East for GBT
- Previous Role: Chief Administrative Officer at Vicarius Pharma
- Passionate about securing great outcomes on fair terms
Sebastian Stachowiak, CEO
Sebastian Stachowiak, CEO
Sebastian Stachowiak, CEO
- Over 20 years experience working in large pharma and biotechs
- Last role: Head of Europe & Middle East for Global Blood Therapeutics (GBT)
- Previous Role: VP Commercial Operations International for TESARO
- Passionate about supporting children with debilitating conditions
Boris Javelle, CFO
Sebastian Stachowiak, CEO
Boris Javelle, CFO
- Over 20 years experience working in large pharma and biotechs
- Last role: Encentrio Group CFO - closed Series A financing
- Previous Role: SVP Head of Europe Nektar Therapeutics
- Passionate about finding innovative solutions to business challenges
About Us
A Powerful and Experienced Leadership Team
A Network of pan-European & Canadian Experts
A Network of pan-European & Canadian Experts
- 60 Years Experience of launching innovative products in Europe & Canada
- Over 1500 Employees hired
- $50m Successfully raised in Series A Funding
- $1b Direct revenue responsibility
- $25b Biotech Buyout Value
A Network of pan-European & Canadian Experts
A Network of pan-European & Canadian Experts
A Network of pan-European & Canadian Experts
We are connected with leading, medical, regulatory, market access and commercial leaders across Europe & Canada, and across multiple therapeutic areas. We will put the best talent behind our partners' assets.
A commitment to Innovation
A Network of pan-European & Canadian Experts
A commitment to Innovation
We are determined to secure equitable access to innovative therapeutics for European & Canadian patients on terms that appropriately reward the innovators